SCHEMBL5022246

SCHEMBL5022246

c1cncc(CCNc2cc(-c3ccco3)nc(-c3nccs3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.47
ADORA1 P30542 4/20 0.47
ADORA3 P0DMS8 3/20 0.47
ADORA2B P29275 3/20 0.47
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 5/20 0.45
HSD17B10 Q99714 3/20 0.45
ALOX15 P16050 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
NAMPT P43490 1/20 0.44
GSK3B P49841 1/20 0.44
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
PTGDR Q13258 1/20 0.43
MYC P01106 1/20 0.43
HPGD P15428 3/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025068 0.81 MAPT (0.56) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5016206 0.77 ADORA2A (0.47) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5023042 0.77 ADORA2A (0.63) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL6038421 0.75 ADORA2A (0.47) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5023009 0.74 MAPT (0.51) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5017713 0.72 ADORA2A (0.72) ADORA2AADORA1ADORA3ADORA2BMYC
SCHEMBL5017695 0.71 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5017656 0.71 MYC (0.52) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5016332 0.71 MYC (0.55) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5024950 0.71 MYC (0.55) ADORA2AADORA1ADORA3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.